carvedilol has been researched along with Diabetes Mellitus, Adult-Onset in 43 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both beta-blockers were well tolerated; use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension." | 9.11 | Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Oakes, R; Phillips, RA; Raskin, P; Wright, JT, 2004) |
| "To compare the metabolic and cardiovascular effects of carvedilol with those of atenolol in diabetic patients with hypertension." | 9.08 | Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. ( Acampora, R; D'Onofrio, F; De Angelis, L; De Rosa, N; Giugliano, D; Marfella, R; Ragone, R; Ziccardi, P, 1997) |
| "To compare the effects of the ACE inhibitor perindopril and the beta-blocker carvedilol on blood pressure and endothelial functions in NIDDM patients with hypertension." | 9.08 | Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. ( Acampora, R; Coppola, L; D'Onofrio, F; Giugliano, D; Giunta, R; Marfella, R, 1998) |
| "The safety and tolerability of carvedilol, a new antihypertensive agent with the combined pharmacological activities of beta-blockade and vasodilation, and of nifedipine were investigated in patients with essential hypertension and non-insulin-dependent (type II) diabetes mellitus." | 9.07 | Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus. ( Adezati, L; Albergati, F; Boeri, D; Lombardo, I; Paternó, E; Semino, S; Venuti, RP; Viviani, GL, 1992) |
| "Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF)." | 8.02 | Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. ( Andersson, C; Gislason, GH; Kristensen, SL; Køber, L; Madelaire, C; Pierce, C; Schou, M; Schwartz, B; Torp-Pedersen, C, 2021) |
| "This study was to assess effects of carvedilol on ventricular remodeling and expression of β3-adrenergic receptor (β3-AR) and Gi protein in a rat model of diabetes subjected to myocardial infarction (MI)." | 7.83 | Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction. ( Fu, L; Kang, X; Shen, J; Wang, F; Wang, Y; Yu, P; Zhang, R, 2016) |
| "Aim of the study was to elucidate peculiarities of influence of carvedilol on 24-hour blood pressure (BP) profiles and changes of parameters of cerebral perfusion in patients with arterial hypertension (AH) associated with type 2 diabetes mellitus." | 7.74 | [Hypotensive activity and cerebroprotective properties of carvedilol in patients with arterial hypertension associated with type 2 diabetes mellitus]. ( Belokopytova, NV; Efimova, IIu; Fal'kovskaia, AIu; Mordovin, VF, 2007) |
| "Carvedilol effects were favorable to adjustment of age as a covariate." | 6.73 | Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives ( ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2008) |
| " As comparisons to metoprolol succinate as well as to optimally dosed metoprolol tartrate are missing, a definite superiority of carvedilol cannot be assumed." | 5.34 | [Beta-adrenoceptor antagonists and ACE-inhibitors. Carvedilol compared with metoprolol as combination partner in cases of diabetes and hypertension]. ( Frese, T; Sandholzer, H, 2007) |
| " As a nonselective β-blocker, carvedilol is employed for treating many cardiovascular diseases in clinical practice, including hypertension, angina pectoris and heart failure, and also exhibit the effectiveness for glycemic control and insulin resistance." | 5.22 | Beneficial effects of carvedilol modulating potassium channels on the control of glucose. ( Li, XT, 2022) |
| "Therapeutic efficiency of spirapryl and its combination with carvedilol in the treatment of diastolic cardiac insufficiency in patients with type 2 diabetes and essential arterial hypertension (AH)." | 5.14 | [Drug therapy of diastolic cardiac insufficiency in patients with type 2 diabetes and concomitant essential arterial hypertension]. ( Borovkov, NN; Iarkova, NA, 2009) |
| "This study shows that vascular insulin sensitivity was preserved during treatment with carvedilol while blunted during treatment with metoprolol in patients with type 2 diabetes." | 5.14 | Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study. ( Christiansen, B; Dominguez, H; Hermann, TS; Kveiborg, B; Køber, L; Major-Pedersen, A; Rask-Madsen, C; Raunsø, J; Torp-Pedersen, C, 2010) |
| "To study efficacy and safety of a preparation of carvedilol Acridilol (Akrikhin, Russia) in patients with mild and moderate arterial hypertension (AH) and obesity and/or compensated type 2 diabetes mellitus (DM)." | 5.13 | [First results of open randomized clinical study of Acridilol in combination therapy of patients with arterial hypertension and obesity or type 2 diabetes (Mellitus-Open Multicenter Clinical Study ACCORD)]. ( Deev, AD; Lukina, IuV; Martsevich, SIu; Oganov, RG; Shal'nova, SA, 2008) |
| " The current analysis of the Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial evaluates the effects of carvedilol and metoprolol tartrate on weight gain in patients with type 2 diabetes and hypertension." | 5.12 | Body weight changes with beta-blocker use: results from GEMINI. ( Anderson, KM; Bakris, GL; Bangalore, S; Bell, DS; Fonseca, V; Holdbrook, FK; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2007) |
| "Thirty-four patients with type 2 diabetes mellitus (T2DM) and hypertension were randomized to receive either carvedilol (n = 16) or metoprolol (n = 18) in addition to their current antihypertensive medications for 5 months." | 5.12 | Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. ( Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM, 2007) |
| "To determine whether the beneficial effects of carvedilol on insulin resistance (IR) are affected by the concomitant use of insulin sensitizers [thiazolidinediones (TZDs) and metformin]." | 5.12 | Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Waterhouse, B; Wright, JT, 2007) |
| "The Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial compared the metabolic effects of two beta-blockers in people with type 2 diabetes and hypertension treated with renin-angiotensin system (RAS) blockade and found differences in metabolic outcomes." | 5.12 | beta-blocker use and diabetes symptom score: results from the GEMINI study. ( Anderson, KM; Bakris, GL; Bell, DS; Dalal, MR; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2007) |
| "Both beta-blockers were well tolerated; use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension." | 5.11 | Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Oakes, R; Phillips, RA; Raskin, P; Wright, JT, 2004) |
| "To compare the metabolic and cardiovascular effects of carvedilol with those of atenolol in diabetic patients with hypertension." | 5.08 | Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. ( Acampora, R; D'Onofrio, F; De Angelis, L; De Rosa, N; Giugliano, D; Marfella, R; Ragone, R; Ziccardi, P, 1997) |
| "To compare the effects of the ACE inhibitor perindopril and the beta-blocker carvedilol on blood pressure and endothelial functions in NIDDM patients with hypertension." | 5.08 | Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. ( Acampora, R; Coppola, L; D'Onofrio, F; Giugliano, D; Giunta, R; Marfella, R, 1998) |
| "The safety and tolerability of carvedilol, a new antihypertensive agent with the combined pharmacological activities of beta-blockade and vasodilation, and of nifedipine were investigated in patients with essential hypertension and non-insulin-dependent (type II) diabetes mellitus." | 5.07 | Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus. ( Adezati, L; Albergati, F; Boeri, D; Lombardo, I; Paternó, E; Semino, S; Venuti, RP; Viviani, GL, 1992) |
| "Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF)." | 4.02 | Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. ( Andersson, C; Gislason, GH; Kristensen, SL; Køber, L; Madelaire, C; Pierce, C; Schou, M; Schwartz, B; Torp-Pedersen, C, 2021) |
| "This study was to assess effects of carvedilol on ventricular remodeling and expression of β3-adrenergic receptor (β3-AR) and Gi protein in a rat model of diabetes subjected to myocardial infarction (MI)." | 3.83 | Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction. ( Fu, L; Kang, X; Shen, J; Wang, F; Wang, Y; Yu, P; Zhang, R, 2016) |
| "The influence of beta-blocker therapy (bisoprolol or carvedilol) (bB) on the prognosis of heart failure (HF) patients with diabetes mellitus (DM) is uncertain." | 3.81 | Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus. ( Andrey, JL; Aranda, RM; Garcia-Egido, A; Gomez, F; López-Sáez, JB; Pedrosa, MJ; Puerto, JL; Rosety, M, 2015) |
| "Aim of the study was to elucidate peculiarities of influence of carvedilol on 24-hour blood pressure (BP) profiles and changes of parameters of cerebral perfusion in patients with arterial hypertension (AH) associated with type 2 diabetes mellitus." | 3.74 | [Hypotensive activity and cerebroprotective properties of carvedilol in patients with arterial hypertension associated with type 2 diabetes mellitus]. ( Belokopytova, NV; Efimova, IIu; Fal'kovskaia, AIu; Mordovin, VF, 2007) |
| "In this study, 1235 participants with type 2 diabetes and hypertension who were receiving renin-angiotensin system blockers were randomized either to carvedilol, receiving 6." | 2.74 | Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. ( Bakris, GL; Bell, DS; McGill, JB, 2009) |
| "Carvedilol effects were favorable to adjustment of age as a covariate." | 2.73 | Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives ( ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Iyengar, M; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT, 2008) |
| "Pharmacological treatment of hypertension can, cause clinically significant alterations in endocrine function and glucose homeostasis." | 2.66 | Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics. ( Ehmer, B; Rudorf, J; van der Does, R, 1988) |
| "The incidence of congestive heart failure is higher in diabetic patients, although the reasons for this increased rate are debated (higher incidence and severity of coronary heart disease and arterial hypertension, or a true diabetic cardiomyopathy)." | 2.41 | [Prevention and treatment of congestive heart failure in diabetic patients]. ( Anguita Sánchez, M, 2002) |
| " This study aims to investigate the implications of type 2 diabetes (T2DM) on the pharmacokinetics of carvedilol enantiomers using an integrated population pharmacokinetic modelling approach." | 1.46 | Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ( Coelho, EB; Della Pasqua, O; Lanchote, VL; Nardotto, GHB, 2017) |
| "Carvedilol is an antihypertensive drug, which is available in clinical practice as a racemic mixture." | 1.43 | Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study. ( Coelho, EB; Lanchote, VL; Marques, MP; Nardotto, GHB, 2016) |
| "We used the non-obese, type 2 diabetes model Spontaneously Diabetic Torii (SDT) rats in this study." | 1.37 | Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes. ( Fujii, H; Fukagawa, M; Goto, S; Hamada, Y; Kitazawa, R; Kitazawa, S; Kono, K; Nakai, K; Nishi, S; Shinohara, M; Yamato, H, 2011) |
| " As comparisons to metoprolol succinate as well as to optimally dosed metoprolol tartrate are missing, a definite superiority of carvedilol cannot be assumed." | 1.34 | [Beta-adrenoceptor antagonists and ACE-inhibitors. Carvedilol compared with metoprolol as combination partner in cases of diabetes and hypertension]. ( Frese, T; Sandholzer, H, 2007) |
| "Participants with hypertension and type 2 diabetes were randomized to either metoprolol tartrate (n=737) or carvedilol (n=498) in blinded fashion after a washout period of all antihypertensive agents except for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers." | 1.33 | Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, F; Phillips, RA; Raskin, P; Waterhouse, B; Wright, JT, 2005) |
| "Carvedilol was administered in 379 hypertensive patients with high risk factors such as NIDDM, lipid disorders or abnormal serum creatinine level and 364 primary hypertensive patients without risk factors." | 1.33 | [Efficiency and safety of carvedilol treatment in high risk hypertensive patients]. ( Hu, DY; Zhao, XL, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.33) | 18.7374 |
| 1990's | 3 (6.98) | 18.2507 |
| 2000's | 20 (46.51) | 29.6817 |
| 2010's | 14 (32.56) | 24.3611 |
| 2020's | 5 (11.63) | 2.80 |
| Authors | Studies |
|---|---|
| Schwartz, B | 1 |
| Pierce, C | 1 |
| Madelaire, C | 1 |
| Schou, M | 1 |
| Kristensen, SL | 1 |
| Gislason, GH | 1 |
| Køber, L | 2 |
| Torp-Pedersen, C | 2 |
| Andersson, C | 1 |
| Li, XT | 1 |
| Bussey, CT | 1 |
| Babakr, AA | 1 |
| Iremonger, RR | 1 |
| van Hout, I | 1 |
| Wilkins, GT | 1 |
| Lamberts, RR | 1 |
| Erickson, JR | 1 |
| Pearson, JT | 1 |
| Thambyah, HP | 1 |
| Waddingham, MT | 1 |
| Inagaki, T | 1 |
| Sukumaran, V | 1 |
| Ngo, JP | 1 |
| Ow, CPC | 1 |
| Sonobe, T | 1 |
| Chen, YC | 1 |
| Edgley, AJ | 1 |
| Fujii, Y | 1 |
| Du, CK | 1 |
| Zhan, DY | 1 |
| Umetani, K | 1 |
| Kelly, DJ | 1 |
| Tsuchimochi, H | 1 |
| Shirai, M | 1 |
| Akinlade, OM | 1 |
| Owoyele, B | 1 |
| Soladoye, OA | 1 |
| Nardotto, GHB | 3 |
| Lanchote, VL | 3 |
| Coelho, EB | 3 |
| Della Pasqua, O | 1 |
| Zullo, AR | 1 |
| Hersey, M | 1 |
| Lee, Y | 1 |
| Sharmin, S | 1 |
| Bosco, E | 1 |
| Daiello, LA | 1 |
| Shah, NR | 1 |
| Mor, V | 1 |
| Boscardin, WJ | 1 |
| Berard-Collins, CM | 1 |
| Dore, DD | 1 |
| Steinman, MA | 1 |
| Mamedov, MN | 1 |
| Garcia-Egido, A | 1 |
| Andrey, JL | 1 |
| Puerto, JL | 1 |
| Aranda, RM | 1 |
| Pedrosa, MJ | 1 |
| López-Sáez, JB | 1 |
| Rosety, M | 1 |
| Gomez, F | 1 |
| Marques, MP | 1 |
| Zhang, R | 1 |
| Kang, X | 1 |
| Wang, Y | 1 |
| Wang, F | 1 |
| Yu, P | 1 |
| Shen, J | 1 |
| Fu, L | 1 |
| Wang, Q | 1 |
| Liu, Y | 1 |
| Fu, Q | 1 |
| Xu, B | 1 |
| Zhang, Y | 1 |
| Kim, S | 1 |
| Tan, R | 1 |
| Barbagallo, F | 1 |
| West, T | 1 |
| Anderson, E | 1 |
| Wei, W | 1 |
| Abel, ED | 1 |
| Xiang, YK | 1 |
| Chen, RJ | 1 |
| Chu, H | 1 |
| Tsai, LW | 1 |
| Paiva, CE | 1 |
| Bell, DS | 9 |
| Bakris, GL | 8 |
| McGill, JB | 8 |
| Shal'nova, SA | 1 |
| Martsevich, SIu | 1 |
| Deev, AD | 1 |
| Lukina, IuV | 1 |
| Oganov, RG | 1 |
| Phillips, RA | 7 |
| Fonseca, V | 7 |
| Katholi, RE | 7 |
| Messerli, FH | 6 |
| Raskin, P | 7 |
| Wright, JT | 7 |
| Iyengar, M | 3 |
| Anderson, KM | 6 |
| Lukas, MA | 7 |
| Iarkova, NA | 1 |
| Borovkov, NN | 1 |
| Kveiborg, B | 1 |
| Hermann, TS | 1 |
| Major-Pedersen, A | 1 |
| Christiansen, B | 1 |
| Rask-Madsen, C | 1 |
| Raunsø, J | 1 |
| Dominguez, H | 1 |
| Goto, S | 1 |
| Fujii, H | 1 |
| Kono, K | 1 |
| Nakai, K | 1 |
| Hamada, Y | 1 |
| Yamato, H | 1 |
| Shinohara, M | 1 |
| Kitazawa, R | 1 |
| Kitazawa, S | 1 |
| Nishi, S | 1 |
| Fukagawa, M | 1 |
| Wai, B | 1 |
| Kearney, LG | 1 |
| Hare, DL | 1 |
| Ord, M | 1 |
| Burrell, LM | 1 |
| Srivastava, PM | 1 |
| Nabbi, R | 1 |
| Riess, ML | 1 |
| Woehlck, HJ | 1 |
| Yasuda, G | 1 |
| Yatsu, K | 1 |
| Yamamoto, Y | 1 |
| Hirawa, N | 1 |
| Anguita Sánchez, M | 1 |
| Oakes, R | 1 |
| Sica, DA | 1 |
| Gonzalez-Feldman, E | 1 |
| Messerli, F | 1 |
| Waterhouse, B | 2 |
| Zhao, XL | 1 |
| Hu, DY | 1 |
| Fardoun, RZ | 1 |
| Drábiková, K | 1 |
| Jancinová, V | 1 |
| Nosál', R | 1 |
| Solík, P | 1 |
| Murín, J | 1 |
| Holománová, D | 1 |
| Dalal, MR | 1 |
| Bank, AJ | 1 |
| Kelly, AS | 1 |
| Thelen, AM | 1 |
| Kaiser, DR | 1 |
| Gonzalez-Campoy, JM | 1 |
| Bangalore, S | 1 |
| Holdbrook, FK | 2 |
| Frese, T | 1 |
| Sandholzer, H | 1 |
| Mordovin, VF | 1 |
| Belokopytova, NV | 1 |
| Fal'kovskaia, AIu | 1 |
| Efimova, IIu | 1 |
| Giugliano, D | 2 |
| Acampora, R | 2 |
| Marfella, R | 2 |
| De Rosa, N | 1 |
| Ziccardi, P | 1 |
| Ragone, R | 1 |
| De Angelis, L | 1 |
| D'Onofrio, F | 2 |
| Giunta, R | 1 |
| Coppola, L | 1 |
| Albergati, F | 1 |
| Paternó, E | 1 |
| Venuti, RP | 1 |
| Boeri, D | 1 |
| Lombardo, I | 1 |
| Semino, S | 1 |
| Viviani, GL | 1 |
| Adezati, L | 1 |
| Ehmer, B | 1 |
| van der Does, R | 1 |
| Rudorf, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00497003] | Phase 4 | 50 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Effects of Carvedilol and Metoprolol on Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus[NCT00123604] | Phase 4 | 36 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Flow mediated dilation is a measure of endothelial function. It is measured by the percent change in artery diameter (i.e. dilation), pre and post manual artery occlusion. (NCT00123604)
Timeframe: change from baseline to 5 months
| Intervention | percentage of change in dilation (Mean) |
|---|---|
| Carvedilol | 6.2 |
| Metoprolol | 4.1 |
4 reviews available for carvedilol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Beneficial effects of carvedilol modulating potassium channels on the control of glucose.
Topics: Antihypertensive Agents; Blood Glucose; Carbazoles; Cardiovascular Diseases; Carvedilol; Diabetes Me | 2022 |
[Arterial hypertension in diabetes mellitus: classical concepts and modern tendencies].
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Comorbidity; Diabetes Mellitus, Type 2; Humans; Hyp | 2013 |
[Prevention and treatment of congestive heart failure in diabetic patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin | 2002 |
Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Diabetes Mellitus, Typ | 2006 |
19 trials available for carvedilol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Area Under Curve; Carba | 2017 |
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2009 |
[First results of open randomized clinical study of Acridilol in combination therapy of patients with arterial hypertension and obesity or type 2 diabetes (Mellitus-Open Multicenter Clinical Study ACCORD)].
Topics: Adrenergic alpha-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilo | 2008 |
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Blood Press | 2008 |
[Drug therapy of diastolic cardiac insufficiency in patients with type 2 diabetes and concomitant essential arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; B | 2009 |
Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Denmark; Diabetes Mellitus, Type 2; Dose-Respon | 2010 |
Effects of carvedilol as third-line add-on therapy on blood pressure and glucose metabolism in type 2 diabetic patients with chronic renal disease stage 3 and above.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood | 2012 |
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2004 |
Current concepts of pharmacotherapy in hypertension. Carvedilol: new considerations for its use in the diabetic patient with hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; C | 2005 |
On the antioxidant activity of carvedilol in human polymorphonuclear leukocytes in vitro and ex vivo.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Antioxidants; Carbazoles; Carvedilol; Di | 2006 |
beta-blocker use and diabetes symptom score: results from the GEMINI study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cognition; Diab | 2007 |
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2007 |
Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Double-Blind Metho | 2007 |
Body weight changes with beta-blocker use: results from GEMINI.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Body Weight; C | 2007 |
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2007 |
Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood | 1997 |
Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Argi | 1998 |
Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; | 1992 |
Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Carbazol | 1988 |
20 other studies available for carvedilol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study.
Topics: Aged; Carvedilol; Denmark; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Metoprolo | 2021 |
Carvedilol and metoprolol are both able to preserve myocardial function in type 2 diabetes.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Animals; Carvedilol; Coronary Artery Bypass; Diabetes | 2020 |
β-blockade prevents coronary macro- and microvascular dysfunction induced by a high salt diet and insulin resistance in the Goto-Kakizaki rat.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Carvedilol; Coronary A | 2021 |
Carvedilol improves heart rate variability indices, biomarkers but not cardiac nerve density in streptozotocin-induced T2DM model of diabetic cardiac autonomic neuropathy.
Topics: Animals; Biomarkers; Carvedilol; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Heart Rate; Human | 2021 |
Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
Topics: Adrenergic beta-Antagonists; Adult; Blood Glucose; Carbazoles; Carvedilol; Cytochrome P-450 CYP2C9; | 2017 |
Outcomes of "diabetes-friendly" vs "diabetes-unfriendly" β-blockers in older nursing home residents with diabetes after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Blood Glucose; Carvedilol; Diabetes Mellitus, Type 2 | 2018 |
Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Case-Control Stud | 2015 |
Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chromatography, Liquid; Diabetes Mellitus, Type | 2016 |
Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Diabetes Mellitus, Experimental; Diabe | 2016 |
Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.
Topics: Animals; beta-Arrestin 2; Carbazoles; Carvedilol; Cells, Cultured; Cyclic Nucleotide Phosphodiestera | 2017 |
Impact of Beta-Blocker Initiation Timing on Mortality Risk in Patients With Diabetes Mellitus Undergoing Noncardiac Surgery: A Nationwide Population-Based Cohort Study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Cohort Studies; Dat | 2017 |
Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Animals; Bone Diseases; Carbazoles; Carvedilol; Diabetes Complications; | 2011 |
Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Biomarkers; Bisoprolol; Carbazole | 2012 |
Angiotensin-receptor-blocker-induced refractory hypotension responds to methylene blue.
Topics: Aged; Angiotensin Receptor Antagonists; Carbazoles; Carvedilol; Citalopram; Crystalloid Solutions; D | 2012 |
Carvedilol, metoprolol, and insulin resistance.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Humans; Hypertension; In | 2005 |
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Carbazoles | 2005 |
[Efficiency and safety of carvedilol treatment in high risk hypertensive patients].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diab | 2006 |
[Beta-adrenoceptor antagonists and ACE-inhibitors. Carvedilol compared with metoprolol as combination partner in cases of diabetes and hypertension].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Diabe | 2007 |
[Hypotensive activity and cerebroprotective properties of carvedilol in patients with arterial hypertension associated with type 2 diabetes mellitus].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Blood Pressure; Blood Pressure Mon | 2007 |
Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2000 |